90% of drugs fail clinical trials.
Vivodyne is changing what happens before that point by testing treatments on 3D lab-grown human tissues instead of animals. Built by CEO Andrei Georgescu and his team, the platform runs robotic experiments on over 100,000 engineered tissues every two weeks, capturing safety, efficacy, and immune response data that’s built for human biology.
Each robotic run generates more human-specific data than all U.S. trials combined. Vivodyne’s platform spans 20 organ types, models diseases like cancer, fibrosis, and autoimmunity, and supports thousands of patient profiles at once. In complex diseases, Vivodyne’s approach improves predictive accuracy from roughly 5% with animal models to 50–100% with human tissues—a tenfold jump that can change the outcome of a trial before it begins.
Most of the top ten pharmaceutical companies are already using it. With $80 million raised to date and a new 23,000-square-foot robotic facility underway in San Francisco, Vivodyne is expanding the infrastructure needed to bring human biology to the center of preclinical testing.
The future of drug development won’t be built in cages. Vivodyne is pushing that frontier forward.
